Matthew Pratt

Prof. Matthew Pratt


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Cell
Verified
Journal Article
Closed access
CPChristopher G. Parker
Christopher G. Parker
MPMatthew Pratt
Matthew Pratt

12 October 2015 in Nature Chemistry
Verified
Journal Article
Open access
PDF file
NMNicholas P. Marotta
Nicholas P. Marotta
YLYu Hsuan Lin
Yu Hsuan Lin
YLYuka E. Lewis
Yuka E. Lewis
MAMark R. Ambroso
Mark R. Ambroso
BZBalyn W. Zaro
Balyn W. Zaro
MPMatthew Pratt
Matthew Pratt
Several aggregation-prone proteins associated with neurodegenerative diseases can be modified by O-linked N-acetyl-glucosamine (O-GlcNAc) in vivo. One of these proteins, α-synuclein, is a toxic aggregating protein associated with synucleinopathies, including Parkinson's disease. However, the effect of O-GlcNAcylation on α-synuclein is not clear. Here, we use synthetic protein chemistry to generate both unmodified α-synuclein and α-synuclein bearing a site-specific O-GlcNAc modification at the physiologically relevant threonine residue 72. We show that this single modification has a notable and substoichiometric inhibitory effect on α-synuclein aggregation, while not affecting the membrane binding or bending properties of α-synuclein. O-GlcNAcylation is also shown to affect the phosphorylation of α-synuclein in vitro and block the toxicity of α-synuclein that was exogenously added to cells in culture. These results suggest that increasing O-GlcNAcylation may slow the progression of synucleinopathies and further support a general function for O-GlcNAc in preventing protein aggregation.

16 January 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PLPaul M. Levine
Paul M. Levine
AGAna Galesic
Ana Galesic
ABAaron T. Balana
Aaron T. Balana
AMAnne-Laure Mahul-Mellier
Anne-Laure Mahul-Mellier
MNMariana X. Navarro
Mariana X. Navarro
MPMatthew Pratt
Matthew Pratt
Significance: Preventing the aggregation of toxic proteins in neurodegenerative diseases is both an important biological function and a potential therapeutic strategy. Here, we examine the consequences of O-GlcNAcylation on the aggregation and toxicity of α-synuclein, the aggregating protein in Parkinson’s disease. α-Synuclein is modified by O-GlcNAc at at least nine different positions in vivo, but the consequences of most of these modifications are unknown. Here, we use synthetic protein chemistry to prepare six different O-GlcNAcylated forms of α-synuclein and show that they have largely inhibitory, but site-specific, effects on the aggregation and cellular toxicity of this protein. These results suggest that O-GlcNAc may be a cellular strategy to prevent protein aggregation, which could potentially be exploited for treatment.

3 May 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
BZBalyn W. Zaro
Balyn W. Zaro
YYYu-Ying Yang
Yu-Ying Yang
HHHoward C. Hang
Howard C. Hang
MPMatthew Pratt
Matthew Pratt
The dynamic modification of nuclear and cytoplasmic proteins by the monosaccharide N -acetyl-glucosamine (GlcNAc) continues to emerge as an important regulator of many biological processes. Herein we describe the development of an alkynyl-modified GlcNAc analog (GlcNAlk) as a new chemical reporter of O-GlcNAc modification in living cells. This strategy is based on metabolic incorporation of reactive functionality into the GlcNAc biosynthetic pathway. When combined with the Cu(I)-catalyzed [3 + 2] azide-alkyne cycloaddition, this chemical reporter allowed for the robust in-gel fluorescent visualization of O-GlcNAc and affinity enrichment and identification of O-GlcNAc-modified proteins. Using in-gel fluorescence detection, we characterized the metabolic fates of GlcNAlk and the previously reported azido analog, GlcNAz. We confirmed previous results that GlcNAz can be metabolically interconverted to GalNAz, whereas GlcNAlk does not, thereby yielding a more specific metabolic reporter of O-GlcNAc modification. We also used GlcNAlk, in combination with a biotin affinity tag, to identify 374 proteins, 279 of which were not previously reported, and we subsequently confirmed the enrichment of three previously uncharacterized proteins. Finally we confirmed the O-GlcNAc modification of the ubiquitin ligase NEDD4-1, the first reported glycosylation of this protein.

20 August 2014 in Journal of the American Chemical Society
Verified
Journal Article
Open access
KCKelly N. Chuh
Kelly N. Chuh
BZBalyn W. Zaro
Balyn W. Zaro
FPFriedrich Piller
Friedrich Piller
VPVéronique Piller
Véronique Piller
MPMatthew Pratt
Matthew Pratt
Metabolic chemical reporters (MCRs) of glycosylation are analogues of monosaccharides that contain bioorthogonal functionalities and enable the direct visualization and identification of glycoproteins from living cells. Each MCR was initially thought to report on specific types of glycosylation. We and others have demonstrated that several MCRs are metabolically transformed and enter multiple glycosylation pathways. Therefore, the development of selective MCRs remains a key unmet goal. We demonstrate here that 6-azido-6-deoxy-N-acetyl-glucosamine (6AzGlcNAc) is a specific MCR for O-GlcNAcylated proteins. Biochemical analysis and comparative proteomics with 6AzGlcNAc, N-azidoacetyl-glucosamine (GlcNAz), and N-azidoacetyl-galactosamine (GalNAz) revealed that 6AzGlcNAc exclusively labels intracellular proteins, while GlcNAz and GalNAz are incorporated into a combination of intracellular and extracellular/lumenal glycoproteins. Notably, 6AzGlcNAc cannot be biosynthetically transformed into the corresponding UDP sugar-donor by the canonical salvage-pathway that requires phosphorylation at the 6-hydroxyl. In vitro experiments showed that 6AzGlcNAc can bypass this roadblock through direct phosphorylation of its 1-hydroxyl by the enzyme phosphoacetylglucosamine mutase (AGM1). Taken together, 6AzGlcNAc enables the specific analysis of O-GlcNAcylated proteins, and these results suggest that specific MCRs for other types of glycosylation can be developed. Additionally, our data demonstrate that cells are equipped with a somewhat unappreciated metabolic flexibility with important implications for the biosynthesis of natural and unnatural carbohydrates.

10 March 2012 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
FMFranziska Meier
Franziska Meier
TATharindumala Abeywardana
Tharindumala Abeywardana
ADAbhinav Dhall
Abhinav Dhall
NMNicholas P. Marotta
Nicholas P. Marotta
JVJobin Varkey
Jobin Varkey
MPMatthew Pratt
Matthew Pratt